AGC Biologics Secures Multi-Hundred-Million-Dollar Commercial Manufacturing Agreement for New Yokohama Site Ahead of 2027 Opening
核心洞察
AGC Biologics has signed a long-term strategic manufacturing agreement with an undisclosed major biopharmaceutical company, with total order value expected to reach several hundred million dollars.
The contract covers commercial production of five biologic drugs, committing to a minimum of 35 batches per year utilizing half of the Yokohama site's mammalian manufacturing capacity.
The new Yokohama facility, slated to begin GMP-compliant services in 2027, will feature 18,000 liters of single-use bioreactor capacity alongside mRNA and cell therapy capabilities.
Ahead of its scheduled 2027 operational launch, AGC Biologics has secured a landmark long-term commercial manufacturing agreement with an undisclosed major biopharmaceutical company, locking in half of the new Yokohama facility's mammalian manufacturing capacity. The multi-year contract is expected to reach a total value of several hundred million dollars, according to AGC Inc. (搜索), the parent company of the Seattle-headquartered CDMO.
The agreement encompasses process transfer, scale-up, regulatory validation, and future commercial production for five biopharmaceutical products. The customer has committed to a minimum of 35 batches per year and will pursue multiple regulatory approvals with the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), UK Medicines and Healthcare products Regulatory Agency (MHRA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA). The manufacturing timeline includes four process performance qualification (PPQ) campaigns within the first two years.
Strategic Significance for Global Supply Chains
The deal reflects a broader industry shift toward supply chain resilience, as global biopharmaceutical developers increasingly prioritize manufacturing partners in geopolitically stable locations. "The market is demanding capable, reliable manufacturing partners with global quality standards and geographic flexibility," said Alberto Santagostino, President and CEO of AGC Biologics. "This agreement reflects the strength of our network, our single-use expertise, and the strategic role Japan can play in resilient biologics supply chains."
Tadashi Murano, President of AGC Life Science Company (搜索), added: "Securing a major commercial partner for Yokohama before the site is operational is a strong signal of confidence in what this facility will offer. With the site located adjacent to the AGC Yokohama Technical Center, biopharmaceutical developers are understanding that choosing a CDMO with an established innovation ecosystem in Japan is a smart outsourcing strategy."
Yokohama Site Capabilities and Infrastructure
Once operational in 2027, the Yokohama site will deploy four 2,000-liter Cytiva single-use bioreactors and two 5,000-liter Thermo Fisher Scientific DynaDrive single-use bioreactors, adding 18,000 liters to AGC Biologics' existing single-use biologics manufacturing capacity. The multi-modality facility is designed to handle biologics using animal cell culture, mRNA therapeutics, and cell therapies, featuring one of the largest animal cell culture bioreactors among domestic CDMOs in Japan.
Services available at the site will include mammalian development and GMP manufacturing with two downstream lines, cell therapy services with six clean rooms, and messenger RNA development and manufacturing with two in-vitro transcription (IVT) lines, two purification lines, and two lipid nanoparticle (LNP) lines.
Government Backing and Industry Context
The Yokohama site was part of biomanufacturing investments made by Japan's Ministry of Economy, Trade and Industry in 2022, aimed at expanding domestic production and reinforcing Japan's position as a trusted biologics partner for life sciences industries within allied nations. Select customers and guests are scheduled to visit the new site in December 2026 upon construction completion.
AGC Biologics brings to the Yokohama operation more than three decades of GMP experience, over 100 successful regulatory inspections, more than 30 commercial products launched with over 100 separate regulatory agency approvals, and more than 400 products developed and manufactured for over 250 different customers. The company's global network spans the U.S., Europe, and Asia, with existing cGMP manufacturing locations in Seattle, Copenhagen, Heidelberg, Milan, and Chiba, Japan.
Under its medium-term management plan, AGC plus-2026, the AGC Group identifies life sciences as a key pillar under its "Well-being" social value category, aiming to contribute to safe, secure, and healthy living through CDMO services spanning diverse modalities from early-stage development through commercial production.